Skip to main content

Table 1 Clinico-pathological parameters for patients with ET and early/prefibrotic PMF

From: Thrombosis in essential thrombocytemia and early/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosis

 

True ET

PMF

p value

M/F

27/34

26/46

n.s.

Median age (years)

58.0 (23–84)

55.5 (20–87)

n.s.

Mean WBC (109/l)

7.5

8.4

p = 0.001

Mean Hb (g/dl)

14.1

14.3

n.s.

Mean PLT (109/l)

751

798

n.s.

Increased LDH (%)

17/45 (37.7%)

18/50 (36.0%)

n.s.

Splenomegaly (%)

12 (19%)

18 (25%)

n.s.

Mean semiquantitative score for granulopoiesis

0.15

1.02

p = 0.001

JAK2V617F-positive (%)

11 (33%)

23 (54%)

n.s.

History of thrombosis (%)

5 (8%)

16 (22%)

p = 0.032

Thrombosis at diagnosis (%)

1 (1.6%)

11 (15.2%)

p = 0.006

Thrombotic events during follow up (%)

7 (11.4%)

11 (15.2%)

n.s.

Progression to overt MF (%)

1 (1.6%)

3 (4.1%)

n.s.

Dead/alive

2/59

8/64

n.s.

Conventional Risk (Low/High)

35/26

30/42

n.s.

Cytoreductive therapy (%)

51 (83%)

64 (88%)

n.s.